Aligos Therapeutics (NASDAQ:ALGS) Trading Up 6.3% – Here’s What Happened

Aligos Therapeutics, Inc. (NASDAQ:ALGS)’s stock price traded up 6.3% on Tuesday . The company traded as high as $5.85 and last traded at $5.77. 104,179 shares traded hands during mid-day trading, an increase of 38% from the average session volume of 75,308 shares. The stock had previously closed at $5.43.

Wall Street Analyst Weigh In

ALGS has been the topic of a number of research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Aligos Therapeutics in a research report on Friday, May 29th. Lake Street Capital initiated coverage on shares of Aligos Therapeutics in a research report on Thursday, May 28th. They issued a “buy” rating and a $45.00 price target for the company. Jefferies Financial Group upgraded shares of Aligos Therapeutics to a “strong-buy” rating in a research note on Thursday, March 26th. Westpark Capital started coverage on shares of Aligos Therapeutics in a report on Thursday, March 26th. They set a “buy” rating and a $48.00 price objective on the stock. Finally, Wall Street Zen raised shares of Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, May 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Aligos Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $38.50.

Aligos Therapeutics Stock Performance

The business has a 50 day moving average of $5.74 and a two-hundred day moving average of $7.30. The stock has a market capitalization of $35.72 million, a PE ratio of -0.66 and a beta of 2.25.

Aligos Therapeutics (NASDAQ:ALGS) last posted its earnings results on Thursday, May 7th. The company reported ($2.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.29) by $0.08. The company had revenue of $2.83 million for the quarter, compared to analyst estimates of $0.25 million. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%. On average, equities analysts expect that Aligos Therapeutics, Inc. will post -7.47 EPS for the current fiscal year.

Institutional Trading of Aligos Therapeutics

A number of institutional investors have recently modified their holdings of ALGS. Woodline Partners LP bought a new position in shares of Aligos Therapeutics during the 1st quarter worth approximately $2,602,000. Geode Capital Management LLC lifted its position in Aligos Therapeutics by 21.3% during the second quarter. Geode Capital Management LLC now owns 34,048 shares of the company’s stock valued at $246,000 after acquiring an additional 5,978 shares during the last quarter. XTX Topco Ltd acquired a new stake in Aligos Therapeutics in the second quarter valued at approximately $100,000. Vanguard Group Inc. boosted its stake in Aligos Therapeutics by 22.8% in the third quarter. Vanguard Group Inc. now owns 171,689 shares of the company’s stock valued at $1,683,000 after acquiring an additional 31,913 shares in the last quarter. Finally, Squarepoint Ops LLC grew its holdings in Aligos Therapeutics by 64.0% in the third quarter. Squarepoint Ops LLC now owns 30,493 shares of the company’s stock worth $299,000 after purchasing an additional 11,904 shares during the last quarter. 60.43% of the stock is currently owned by institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical?stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small?molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.